Michael Best Represents ReSync Bio in Strategic Transaction

Michael Best represented ReSync Bio in their recent transaction with Benchling, a cloud-based software platform powering the biotechnology industry. ReSync Bio developed software to accelerate drug discovery. Working in small molecule discovery, ReSync’s platform helped scientists run the latest scientific AI models without building their own compute infrastructure. This transaction will help make AI a part of everyday scientific research.

The Michael Best team was led by Brett Valentyn, in conjunction with Shawn Stigler, as well as Elaina Bailey, Justin Mertz, Carley Peterson, Jeff Peterson, and Duncan Williams.

Learn more about Michael Best’s M&A team and capabilities here.